Barry Quart Sells 20,129 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Director Barry Quart sold 20,129 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $520,784.46. The trade was a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kiniksa Pharmaceuticals International Price Performance

Shares of KNSA stock opened at $42.00 on Friday. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $42.98. The firm has a market capitalization of $3.18 billion, a P/E ratio of 93.34 and a beta of 0.02. The company’s fifty day moving average price is $40.11 and its two-hundred day moving average price is $34.84.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The business had revenue of $180.86 million for the quarter, compared to analyst estimates of $166.64 million. During the same quarter in the prior year, the business earned ($0.18) earnings per share. The firm’s revenue was up 61.2% on a year-over-year basis. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Citigroup lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. TD Cowen started coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a “buy” rating and a $60.00 price objective on the stock. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $52.00.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 137.4% in the 1st quarter. Invesco Ltd. now owns 33,492 shares of the company’s stock worth $744,000 after purchasing an additional 19,384 shares during the last quarter. Savant Capital LLC bought a new position in Kiniksa Pharmaceuticals International during the 2nd quarter worth $398,000. Vanguard Group Inc. increased its position in Kiniksa Pharmaceuticals International by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after buying an additional 151,604 shares during the period. Wellington Management Group LLP lifted its stake in Kiniksa Pharmaceuticals International by 30.4% in the first quarter. Wellington Management Group LLP now owns 91,032 shares of the company’s stock valued at $2,022,000 after buying an additional 21,219 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 170.3% during the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company’s stock valued at $22,961,000 after acquiring an additional 651,700 shares during the period. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.